Ligand validation:6R13

EF2: S-Thalidomide

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6R13_EF2_A_202	71%	2%	0.097	0.919	3.14	3.32	5	15	1	0	100%	1
5AMI_EF2_B_151	97%	4%	0.049	0.974	2.57	3.08	6	15	0	0	100%	1
5AMJ_EF2_B_151	97%	6%	0.055	0.977	2.83	2.2	6	11	0	0	100%	1
5AMH_EF2_A_151	96%	10%	0.056	0.976	2.06	2.19	8	10	0	0	100%	1
4V2Y_EF2_B_151	96%	3%	0.059	0.979	2.76	3.09	6	14	0	0	100%	1
7PSO_EF2_B_202	96%	7%	0.059	0.975	2.1	2.67	5	12	0	0	100%	1
5YJ0_EF2_A_501	100%	11%	0.029	0.992	2.21	1.9	4	12	0	0	100%	1
5YIZ_EF2_J_501	99%	12%	0.039	0.984	2.15	1.87	4	12	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729. RCSB PDB uses resources of the National Energy Research Scientific Computing Center (NERSC), a Department of Energy User Facility.